{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is CohBar, Inc. technically bullish or bearish?
As of October 1, 2023, there is not enough technical data for CohBar, Inc. to determine if it is bullish or bearish.
Who are in the management team of CohBar, Inc.?
As of March 2022, the management team of CohBar, Inc. includes Mr. Albion Fitzgerald (Independent Chairman), Mr. Steven Engle (CEO), and several independent directors: Mr. Jon Stern, Dr. Nir Barzilai, Dr. Pinchas Cohen, Dr. Phyllis Gardner, and Mr. David Greenwood. They oversee the company's strategic direction and operations.
What does CohBar, Inc. do?
CohBar, Inc. is a clinical stage biotechnology company developing mitochondria-based therapeutics for chronic and age-related diseases, with a market cap of $1.19 million and a recent net profit of -$4 million. The company operates in the micro-cap market and has no dividend yield or positive return on equity.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
